Anti-β2-glycoprotein I (anti-β2GPI) antibodies are central to the pathogenesis of antiphospholipid syndrome (APS), an autoimmune disease characterized by a strong predisposition to venous thromboembolism (VTE). This evidence concerns the gene APOH and autoimmune polyendocrinopathy.